Jump to the top of the page

Investment Banking

The Quarterly Rx: 2022 Year in Review U.S. Biopharma Recap

After an undoubtedly challenging year for the biopharma sector in which macroeconomic risk weighed on investor sentiment, we began to see signs of stability to close out 2022 – prompting increased optimism for a recovery in 2023. William Blair's Biopharma team shares perspectives in The Quarterly Rx: 2022 Year in Review U.S. Biopharma Recap.

William Blair’s 2023 Predictions

  1. Volatility is here to stay, but “hard landing” is unlikely
  2. Biopharma sector will outperform the broader market
  3. Steady cadence of private financings, but “crossover” activity will remain muted
  4. IPOs will return, but insider support will remain critical
  5. Follow-on activity will continue to increase
  6. M&A activity in-line with 2022, but overall partnering to increase

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Opportunities in Aerospace and Defense Applications

    Jesse Fink, CFA, a research analyst on our U.S. value equity team, tours a facility involved in the research and development of 3D woven composite technologies for aerospace and defense applications.

    Watch the video

  • Rollover Equity and Wealth Planning Considerations

    Business owners in the run-up to a liquidity event are well advised to learn about the practices and approaches common in transactions. Among the most important is rollover equity—i.e., when a seller agrees to reinvest sale proceeds in the newly formed company.

    Read more

  • Opportunistic Activity Defies Gravity

    Opportunistic activity soared in the fourth quarter as borrowers capitalized on tightening spreads, closing out a record-setting year driven by the combination of rate cuts, a more stabilized economic outlook, and robust investor demand.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures